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Abstract
Background: While there is no breakthrough progress in the medical treatment of essential tremor (ET), in the past decades several remarkable achievements
happened in the surgical field, such as radiofrequency thalamotomy, thalamic deep brain stimulation, and gamma knife thalamotomy. The most recent advance in
this area is magnetic resonance-guided focused ultrasound (MRgFUS).
Methods: The purpose of this review is to discuss the new developments and trials of MRgFUS in the treatment of ET and other tremor disorders.
Results: MRgFUS is an incisionless surgery performed without anesthesia and ionizing radiation (no risk of cumulative dose and delayed side effects). Studies have
shown the safety and effectiveness of unilateral MRgFUS-thalamotomy in the treatment of ET. It has been successfully used in a few patients with Parkinson’s
disease-related tremor, and in fewer patients with fragile X-associated tremor/ataxia syndrome. The safety and long-term effects of the procedure are still unclear,
as temporary and permanent adverse events have been reported as well as recurrence of tremor.
Discussion: MRgFUS is a promising new surgical approach with a number of unknowns and unsolved issues. It represents a valuable option particularly for
patients who refused or could not be candidates for other procedures, deep brain stimulation in particular.
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Introduction
Essential tremor (ET) is a common movement disorder, the most
common one in the adult population. According to some studies its
prevalence reaches up to 9% in people older than 60 years.1 It usually
presents as a bilateral postural 8–12 Hz tremor of the hands, followed
by a kinetic and resting component too; the upper limbs are usually
symmetrically involved but with disease progression the head and
voice (less commonly legs, jaw, face, and trunk) may be involved too.2
The etiology of ET is not clearly understood probably as a result of
the heterogeneity of the underlying pathological process; in fact, ET
possibly represents a syndrome rather than a defined disease.3 Accord-
ingly, although a strong family history has been reported in many
families with an autosomal dominant pattern of inheritance, no major
causal gene has been identified so far.
A significant percentage of ET patients never visit a physician since
the symptoms are mild and non-disturbing; but in some patients the
symptoms (kinetic tremor in particular) are severe enough to inter-
fere with daily activities and cause social embarrassment.4 In these
cases treatment is recommended.1,5 Figure 1 depicts a possible treat-
ment flowchart of ET: the first-line agents are propranolol, primidone,
and topiramante, each of these agent should be used alone up to the
Freely available online
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services1
highest tolerated dose and when ineffective they can be used in combi-
nation; many other second- and third-line agents can be added (e.g.,
gabapentin, clonazepam, botulinum neurotoxin injections) but these
rarely suffice. In this scenario (i.e., tremor affects the quality of life and
it is drug resistant), surgery should be considered. It has been estimated
that medical treatments are not effective or not tolerated in about 50%
of ET patients.1,6
While there is no significant progress in the medical field of ET, the
surgical field has been very active and there are advances in this area.7
The surgical modalities used for ET include three major categories: 1)
ablation (i.e., thalamotomy), 2) deep brain stimulation (DBS) of the
ventrointermedius nucleus (Vim) of the thalamus, and 3) non-invasive
(e.g., transcranial magnetic stimulation) and superficial brain stimula-
tion (e.g., extradural or subdural motor cortex stimulation), which
are still experimental and will not be discussed further.8 There are
different types of ablative therapies: a thalamotomy can be performed
by using radiofrequency (RF), the gamma knife (GK), and the recently
introduced magnetic resonance-guided focused ultrasound (MRgFUS).7,9
These ablative (i.e., destructive) techniques can be further divided into
invasive (RF) or non-invasive (GK and MRgFUS) techniques. Table 1
highlights the principal features of the non-experimental surgical
options available thus far.
In this review we will critically review the role of MRgFUS-
thalamotomy in the treatment of ET, explaining the technique, mech-
anism of action, benefits, and side effects.
Review methods
We performed a review by searching MEDLINE and using the key
words ‘‘focused ultrasound,’’ ‘‘magnetic resonance guided focused
ultrasound,’’ ‘‘focused ultrasound thalamotomy’’ or ‘‘magnetic reso-
nance guided focused ultrasound thalamotomy.’’ A targeted search of
the bibliographies of relevant articles was also performed to identify
additional studies. Only original articles published in English until
January 2017 were included in this review. In case of a partly over-
lapping patient population reported by the same group, the study with
the largest population was chosen and in case of a dual publication,
Figure 1. A Decision Tree for the Treatment of Tremor. In patients with a limb tremor, unilateral procedure (either DBS or ablation) may sometimes be
sufficient to reduce the disability. In the case of disabling bilateral limb, head, voice, or trunk tremors, a bilateral procedure is necessary. As bilateral thalamotomies
carry a high risk of dysarthria, dysphagia or balance problems, mostly Vim-DBS is applied. Other less studied targets are the Zi, especially in its caudal part (Raprl),
Vop and Voa nuclei of the thalamus (modified from ref. 75). BoNT, Botulinum Neurotoxin; DBS, Deep Brain Stimulation; EMG, Electromyogram; GA, General
Anesthesia; GKRS, Gamma Knife Radiosurgery; M/C, Midline and/or Contralateral Tremor; MCS, Motor Cortex Stimulation; MRgFUS, MRI-guided Focused
Ultrasound (of Vim); QoL, Quality of Life; Raprl, Prelemniscal Radiation; RF, Radiofrequency; rTMS, Repetitive Transcranial Magnetic Stimulation; Vim,
Ventrointermedius Nucleus of the Thalamus; Voa, Ventral Oral Anterior of the Thalamus; Vop, Ventral Oral Posterior Nucleus of the Thalamus. *To be considered in
patients with a severe bleeding risk (e.g., ongoing anticoagulation). **Medication reduction can contribute to the worsening of midline/contralateral tremor.
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the study was considered once. In total we included 30 articles on
MRgFUS in humans. Other included papers were reviews or original
articles on technical aspects and experimental uses (e.g., animal
studies) of FUS.
History
For years ultrasound has been used as an effective diagnostic tool in
almost all fields of medicine and also as a therapeutic instrument in
some areas. Examples of the latter are renal stones (lithotripsy) and
cataract surgery (phacoemulsification).10 The use of high-intensity
focused ultrasound (HIFU) for ablation of living tissues goes back to
the 1940s when Lynn11 ablated fresh liver tissue without destruction of
surrounding areas and then moved to the brain of living animals. The
Fry brothers further explored HIFU to ablate brain tissues.12,13 In
1959 their experience led to its first-time application in the treatment
of tremor in patients with Parkinson’s disease (PD) in whom the globus
pallidus was ablated after part of the skull bone was removed.14 Later
on, with the discovery of levodopa and afterward DBS, the role of
ultrasound in treating movement disorders faded out. In the 1990s
the combination of magnetic resonance imaging (MRI) with HIFU
brought renewed interest in its use for the treatment of neurologic
disorders.10
Technical aspects of MRgFUS
MRgFUS is a relatively new modality of treatment based on two
technologies, the aforementioned HIFU and MRI to plan targeting
and monitor the treatment real time, also using temperature maps.
Preclinical animal models demonstrated the safety, validity, and effi-
cacy of this technology in generating brain lesions and disrupting the
blood–brain barrier (BBB).15 Subsequently, HIFU entered clinical
practice, being widely used for a number of approved applications,
including accelerating fracture repair16 and non-invasive ablation of a
Table 1. The Features of the Neurosurgical Procedures Currently Used for Movement Disorders (listed chronologically).31,49,59




Technique A probe inserted into the
brain is used to burn
neurons in a selected area
to create a focal lesion
One or more electrodes are
inserted into the brain and are















intact skull to generate a
















Over 50 years Over 30 years Over 15 years 4 years
Ablation
(irreversible effects)
Yes No Yes Yes
Use of general
anesthesia
No Yes No No
Invasive/incisions Yes Yes No No
Possibility of
bilateral procedure
No Yes No No
Device
implantation
No Yes No No
Benefit onset Immediate Delayed (when programming
is completed, up to 6 months)
Delayed (up to 1
year)
Immediate
Abbreviation: MRI, Magnetic Resonance Imaging.
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variety of benign and malignant tumors, such as uterine fibroids, breast
cancer, bone metastasis, and prostate tumors.17–21
The lesional power of ultrasound is based on two major mech-
anisms: thermal and non-thermal.10 As for the former, the therapeutic
goals of MRgFUS can be defined according to the level of ultrasound
energy provided: low-intensity FUS (LIFU) can reversibly affect neural
function, thus representing another way to perform neuromodulation;
moderate energy levels can be employed to safely open the BBB for
different aims (e.g., localized delivery of therapeutics); HIFU is
sufficient to create a coagulation lesion in the brain with the goal of
developing a minimally invasive way to create focal brain lesions. In
fact, at a temperature of over 44 C̊ for some seconds, irreversible cell
death by coagulative necrosis will occur.22 To reach these temperatures,
usually an equal amount of ultrasound energy is applied con-
tinuously. As the energy absorption in the ultrasound beam path is
lower, the surrounding tissue is spared.22 Ultrasound’s non-thermal
effects are due to alternating pressure and subsequently formation
of air bubbles, a process termed acoustic cavitation. It has been
hypothesized that adverse effects are due to non-thermal effects,
so that the production of bubbles should be avoided during the
procedure.23,24
Poor penetration of ultrasound in the skull was a barrier to using
ultrasound for intracranial and brain diseases. This problem was
solved by a system preventing the heating of the cranium bones. It
consists of a spherical, phased array, multi-element transducer helmet
operating at a frequency of 0.5–1.5 MHz that allows focusing of
ultrasound energy coupled with software that compensates for skull-
induced wavefront distortions.25,26
The typical patient treatment protocol includes a preoperative
computed tomography scan of the entire cranium to measure skull
thickness. On the treatment day, a frame is fixed to the shaved head of
the patient under local anesthesia; at the same time the scalp is
inspected for scars and other lesions that could compromise the
passage of ultrasound. Then an elastic diaphragm filled with cool water
is attached to the scalp and connected to the ultrasound transducer
(Exablate Neuro, Insightec, Tirat Carmel, Israel). The procedure is
done in an MRI unit without general anesthesia and sedatives.
During the procedure a series of low-power ‘‘sonications’’ (40–45 C̊)
confirmed the accurate targeting and focusing, as these ‘‘test lesions’’
do not induce permanent changes but are enough to induce a tran-
sient effect, either positive or negative. Next, by gradual increment
of the duration of sonication the lesion is progressively created
and enlarged until a satisfactory clinical effect is reached.27,28 The
temperature at the target is monitored by proton resonance frequency
through MR thermometry. The location and size of the lesion, the
clinical effects, and the side effects are monitored continuously by
assessing the alert patient during the surgery. Pain and burning
sensations, and the discomfort caused by prolonged lying are managed
accordingly, usually by an anesthesiologist who is present during the
procedure. Overall, the treatment lasts 3–4 hours and ends once
the clinical and radiologic effects are deemed satisfactory. Following
the procedure, the patient undergoes a neurological examination
in the recovery room, and post-treatment MR images are obtained to
assess the lesion location and size (Figure 2).
MRgFUS in neurological diseases
Virtually any brain structure can be targeted with MRgFUS using
a stereotactic atlas and neuroimaging. Refractory neuropathic pain
was the first application of this technology in a study on nine patients
with different types of pain in whom the centrolateral thalamus was
targeted: all of them reported immediate improvement and 57% pain
relief at the 1-year follow-up.29 More recently, MRgFUS targeting the
anterior limb of the internal capsule (capsulotomy) was performed in
four patients with obsessive compulsive disorder (OCD), resulting in a
33% reduction of the Yale–Brown OCD scale and a significant
improvement of anxiety and depression.30
Among the neurological indications, tremor is the most explored
disorder and also the first to receive Food and Drug Administration
(FDA) approval, in July 2016. This has been possible for several
reasons: 1) RF thalamotomy and Vim-DBS have a long tradition in
patients with medically refractory ET;9,31 2) the Vim is centrally
Figure 2. Neuroimaging of Neurosurgical Procedures for Tremor. Brain MRI of a tremor patient 1 day and 6 months after MRgFUS-thalamotomy of
the left hemisphere (right). CT scan of another tremor patient who underwent left RF-thalamotomy (arrow) followed by right Vim-DBS (left). DBS, Deep Brain
Stimulation; DWI, Diffusion-weighted Imaging; MRgFUS, MRI-guided Focused Ultrasound (of Vim); RF, Radiofrequency; T2w, T2-weighted Imaging; Vim,
Ventrointermedius Nucleus of the Thalamus.
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located within the brain, which reduces the distortional effects of the
skull on focusing the ultrasound energy; 3) tremor can be easily assessed
during the procedure; 4) tremor reduction can substantially reduce
disability with unilateral treatment just treating the dominant hand.
MRgFUS for tremor is the focus of this review and it will be
discussed in depth in the following paragraphs.
MRgFUS-thalamotomy in ET
There are multiple small-sample studies on the efficacy of
MRgFUS-thalamotomy in the treatment of ET. Lipsman and col-
leagues27 reported the very short-term results in four patients with
refractory ET: there was a remarkable reduction of tremor score of the
operated hand, by 89.4% and 81.3% at the 1- and 3-month follow-up
visits, respectively. One of their patients had persistent paresthesia and
another one developed deep vein thrombosis, probably related to the
long immobilization associated with the procedure.27 Elias et al.28
reported their results in 15 ET patients followed up for 1 year, showing
a significant improvement of hand tremor scores (reduced by 74.5%)
as well as quality of life and disability scores. Chang and colleagues24
performed unilateral MRgFUS-thalamotomy in 11 ET patients, but
the skull thickness did not allow the required therapeutic temperature
in the thalamus to be reached in three of them; analyzing the data of
eight patients up to 6 months after the procedure, the authors found a
significant improvement of tremor.24
The largest study published so far is a multicenter randomized con-
trolled clinical trial study that enrolled 76 ET patients and allocated
them to unilateral MRgFUS-thalamotomy or sham surgery with a 3:1
ratio.32 Hand tremor scores improved by 47% at the 3-month assess-
ment (primary endpoint), a significant difference from patients who
received a sham procedure (improved by only 1%); the benefit
decreased at the 12-month assessment (40% improvement compared
with baseline). Adverse events were commonly reported, including
paresthesia and balance disturbances, respectively seen in 14% and
9% of patients at the end of the observation period.32
Other targets of MRgFUS in ET
Gallay et al.33 used MRgFUS to perform cerebellothalamic tracto-
tomy (CTT) in 21 ET patients. Three of the patients successively
underwent a bilateral procedure 1 year later. All the patients showed
significant and sustained improvement of tremor scores at the 1-year
evaluation. However, pre-existing gait imbalance worsened in five
patients, only temporarily in four of them.33 Overall, the study showed
acceptable tolerance of bilateral CTT, which can be a potential
advantage of this target compared to Vim, where bilateral ablations
can cause serious side effects such as imbalance, gait problems, and
cognitive and speech disturbances.31
Vim-MRgFUS in non-ET tremors
Vim-MRgFUS has been used for tremor associated with PD.
Tremor ceased after treatment in all subjects in a case series of seven
patients but recurred in a mild form in three of them 6 months later;
the procedure was associated with a significant improvement in quality
of life.34 A blinded sham-controlled study for PD tremor is currently
ongoing and preliminary results are only available in abstract
form.35,36 In this study, 27 patients with tremor-dominant PD received
either a unilateral MRgFUS-thalamotomy or sham surgery with a 2:1
ratio. The sham group received surgery after 3 months. The 1-year
tremor scores for all 19 patients completing the follow-up period
showed a significant reduction of tremor scores by 41% and of the
Unified PD rating scale (UPDRS) on medication by 32%. However,
the 3 months results were not significantly different between the two
groups because of a significant placebo effect in patients receiving
sham surgery (22% tremor reduction).36
Reports on two patients with fragile X-associated tremor/ataxia
syndrome effectively and safely treated with unilateral MRgFUS-
thalamotomy have been recently published.37,38 We have seen the
same promising results in a small series of patients with dystonic
tremor and ET-like tremors seen in dystonia patients (tremor asso-
ciated with dystonia and tremor associated with dystonia gene)
(personal unpublished experience).
Other targets of MRgFUS in non-ET tremors
Magara and colleagues39 for the first time performed unilateral
pallidothalamic tract (the confluence of the ansa lenticularis and
lenticular fasciculus) ablation using MRgFUS in 13 patients with
tremor-dominant PD. Their first four patients underwent the same
protocol used for thalamic procedures but they experienced recurrent
symptoms 3 months later. Therefore, the remaining nine patients were
treated with four or five repetitions of the same protocol. At the
3-month follow-up, an average reduction of 61% of the total score
UPDRS and 57% of the Global Symptom Relief was reported. The
use of multiple sonications was likely attributed to the different tissue
reactions of white matter tracts compared with grey matter, as also
observed in a patient receiving MRgFUS-anterior limb capsulotomy
for OCD.30,39
Na and coworkers40 reported the first unilateral MRgFUS-pallidotomy
in a PD patient with levodopa-induced dyskinesias who achieved a reduc-
tion of UPDRS on and off medication by 60% and 55%, respectively.
MRgFUS-thalamotomy compared to other surgical
modalities
Classic thalamotomy is done by inserting an electrode through a
craniotomy, generating thermal energy by means of RF. With intra-
operative microelectrode recording and macrostimulation, it is possible
to precisely assess the target for benefits and adverse effects before a
permanent ablation is made. No general anesthesia is needed. On the
other hand, the invasiveness of the technique increases the risk of
infection and hemorrhage.31 Unilateral or bilateral Vim-DBS share
similar features (particularly the invasiveness and targeting with
microelectrode recording and macrostimulation) and similar potential
risks of hemorrhage and infection, the latter being even higher as
hardware is implanted in the body and also because the battery has to
be changed every 3–6 years. In addition to hardware implantation,
DBS has two main differences: it requires general anesthesia (in order
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to insert the battery in the chest) and it can be adjusted to opti-
mize control of symptoms and side effects over the years. The
international randomized controlled trial comparing standard
RF-thalamotomy and Vim-DBS concluded that although both
treatments yield similar tremor control in the short-term, DBS is
safer and guarantees better tremor control in the longer term at the
price of possible hardware-related complications.41 Furthermore,
the reversibility of DBS allows the insertion of the electrode in the
hemisphere contralateral to the first operated side (regardless of the
first procedure type).42 In fact, DBS is the only non-ablative surgical
procedure used for tremor treatment, and it is well known that the
risk of gait and balance disturbance, and cognitive and speech
difficulties is intolerably high with bilateral ablative procedures.31
Targeting both hemispheres has the advantage of improving the
tremor of both body sides and also axial symptoms, such as head,
face, and voice tremor.43
Bilateral DBS (or DBS contralateral to another ablative treatment
previously done) is not risk-free with respect to ataxia symptoms;
however, these are usually reversible with further adjustments of
stimulating parameters.44 Recently, prolonged bilateral Vim-DBS has
been linked to a delayed pseudo-progressive ataxia syndrome that can
be reverted by turning stimulation off for several days.45
GK thalamotomy is a non-invasive and incisionless procedure
without risk of hemorrhage and infection.46,47 Targeting is based on
anatomy without microelectrode recording and stimulation of the
target before permanent ablation. Since its results are delayed for
weeks to months, assessment of the positive and side effects during the
procedure is not possible. These delayed effects can also cause further
progression of the lesion, thus causing unpredictable progressive side
effects.48,49
Tables 1 and 2 summarize the features of the current neurosurgical
approaches to tremor. No head to head randomized trial comparing
the newer surgical treatments has been performed so far and therefore
any comparison is speculative. Nevertheless, a comparison can be
certainly driven by clinical experience and previous comparative studies.
Huss and colleagues43 performed a retrospective study comparing the
results of unilateral MRgFUS-thalamotomy (15 patients) with bilateral
or unilateral thalamic DBS (57 and 13 patients, respectively). They
showed similar positive results regarding tremor reduction and quality
of life improvement across the three groups. Not surprisingly, this
study found better midline and bilateral tremor control with DBS
targeting both hemispheres; interestingly, unilateral Vim-DBS was
superior to unilateral MRgFUS-thalamotomy in the control of midline
tremors.43









Possible target(s) Vim Yes Yes Yes Yes
Vop Yes Yes No No
GPi Yes Yes (Yes)a Yes
STN (Yes)a Yes No No
Zi (Yes)a Yes No No
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Risks Brain bleedingc Yes Yes No No?
Infection Yes Yes No No
Hardware
malfunction
No Yes No No
Temporary side
effectsd
Yes Yes No Yes
Permanent side
effectsd
Yes No Yes Yes
Hyper-response of
brain tissuee
No No Yes Yes
Radiation-related
(delayed effects)
No No Yes No
Other features Need of being
monitored/multiple
visits
No Yes No No
Need of battery
changes
No Yes No No
Adjustable over time No Yes No No
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Abbreviations: DBS, Deep Brain Stimulation; GPi, Globus Pallidus Pars Interna; MRI, Magnetic Resonance Imaging; STN, Subthalamic Nucleus;
Vim, Ventrointermedius Nucleus of the Thalamus; Vop, Ventro-oralis Posterior Nucleus of the Thalamus; Zi, Zona incerta.
aLimited experience.
bNot in case of intraoperative complications (e.g., stroke).
cCausing no symptoms, stroke-like symptoms, death.
dParesthesia, sensory loss, weakness, ataxia, visual field defects, speech and swallowing difficulties NOT caused by an intraoperative
complication (e.g., stroke).
eUnpredictable brain tissue reaction characterized by edema and non-radial spreading of the lesioning effects.
fBut no further MRI after the procedure (selected manufacturers).
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Although limited, the aforementioned considerations should guide
clinicians in the selection of the best surgical option for movement
disorders, tremor in particular. In our opinion, DBS has significant
advantages and should be favored when possible. Figure 1 depicts a
possible decision tree for the selection of tremor patients needing surgery.
The current hurdles of MRgFUS
During a relatively short period of time, MRgFUS has become
extremely popular and clinical experience is rapidly growing. This
process has already identified a number of problems, detailed in Table 3.
MRgFUS procedures have been associated with a variable outcome:
for example, tremor reduction ranged from –20% to +88% in the
largest RCT performed so far.32 The same trial has also found that
tremor control degraded by 23% over the first year, thus pointing to
the possibility that the combination of brain healing and tremor
progression will not guarantee enough symptomatic relief in the
medium and long term.32
MRgFUS is perceived as a safe procedure but it has been associated
with a relatively high number of persistent side effects: 9% of gait
disturbance and 14% of paresthesia 1 year after surgery in the recent
aforementioned large trial.32 MRgFUS-thalamotomy is created with-
out electrophysiological localization techniques that were developed
for RF thalamotomy (intraoperative recording and stimulation). Given
the fact that the main danger posed by RF-thalamotomy is not the
incision, burr hole, or electrode pass but the ablation itself, it has been
recently commented that ‘‘MRgFUS thalamotomy may actually be
riskier than classic RF-thalamotomy, which, in turn, is riskier than
DBS.’’50 On the other hand, during the MRgFUS procedure real-time
brain MRI is used to monitor target localization and the size of the
ablation area. Another still not fully elucidated problem is the unpredic-
table brain tissue reaction seen in some patients, a phenomenon already
reported in GK procedures.47 It consists of a large amount of edema and
non-radial spreading of lesioning effects. The former is typically asso-
ciated with transient adverse effects; the latter is more dangerous and its
Table 3. The Problems, Unknowns, and Possible Future Indications (based on experimental evidence) of FUS.
Problems
Variable effects on symptoms control
Decay of tremor control in the short term
Relatively high number of persistent side effects
Unpredictable hyper-response of brain tissue
Not suitable to target both hemispheres
Not possible in patients with MRI contraindications
Not possible in patients with high skull thickness
Not possible in patients with previous brain surgery
Limited experience
Patients’ misperception of being non-surgical
Unknowns
Long-term effects
Re-operation of the same brain area (e.g., in case of tremor recurrence)
Efficacy of lesioning less centered brain targets (e.g., GPi)
Safety of bilateral procedures
Efficacy of DTI MRI to better target brain nuclei/fibers
Safety of STN lesioning (risk of hemiballismus)
Bleeding risk in selected populations (e.g., patients on anticoagulants)
Impact of placebo effect in previous and future RCTs
Possible future applications
Opening the BBB using moderate-intensity pFUS to improve the delivery of therapeutic agents (growth factors and genes)60–68
Improving the spread of nanoparticles combined with CED for the delivery of protein and gene therapy to the brain69
Neuromodulation with a high degree of spatial resolution (either activation60,70 or suppression of neuronal activity71) using low-intensity pFUS
‘‘Enhanced sonication’’ through inertial cavitation by microbubbles compressed and expanded by FUS72
Sonothrombolysis of clotted blood in ICH, thereby facilitating minimally invasive evacuation of the clot via craniostomy and aspiration tube73
Abbreviations: BBB, Blood–Brain Barrier; CED, Convection Enhanced Delivery; DTI, Diffusion Tensor Imaging; FUS, Focused Ultrasound; GPi:
Globus Pallidus Pars Interna; ICH, Intracerebral Hemorrhage; pFUS, Pulsed-mode Focused Ultrasound; RTC, Randomized Controlled Trial;
STN, Subthalamic Nucleus.
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phenomenology probably relies on the anatomy of the targeted area (fiber
directions and ratio between neuronal bodies and axons).
Another problem of MRgFUS for movement disorders is related to
the fact that many patients need bilateral procedures and this limits in
particular the usefulness of this technique in pallidotomies performed
to treat diseases such as dystonia or PD. In addition, it is not empha-
sized enough that many patients cannot undergo MRgFUS; examples
include patients with pacemakers or other contraindications to MRI
or patients with high skull thickness. In fact, a study on 25 patients
(one with PD, 15 with ET, and nine with OCD) found that skull
volume and density significantly affect the maximum temperature
achieved in the deep brain.51 For example, patients with high skull
density may undergo skin lesions and local pain in order to receive
enough lesioning energy in the deep brain. Another contraindication
of MRgFUS is a history of previous brain surgery, because some of
these patients’ brain areas may receive more energy than predicted by
software, assuming that the entire skull is intact.
Probably the most important hurdle of MRgFUS is related to the
many unknowns of a relatively new treatment that gained popularity
rather fast. In this respect, although public opinion and patients
perceive it as a ‘‘non-surgical’’ intervention, MRgFUS is not risk-free.
This virtually puts many people at risk, as ET is the most prevalent
movement disorder and up to 50% of patients become refractory or
intolerant to medication.6
Table 3 also lists the unknowns of MRgFUS: we already touched on
the possible long-term decay of benefit and it is currently unknown
whether reoperation of the same target is feasible and safe. The
lesioning power of MRgFUS is very strong in the central brain target
(such as the thalamus) but full impact on more lateral structures such as
the GPi is currently unknown. As mentioned earlier, MRgFUS is only
performed unilaterally in patients with movement disorders because of
safety concerns. However, it has been used to induce bilateral lesions in
other indications and it is therefore possible that the further develop-
ment of targeting procedures will make bilateral lesions possible with
a staged fashion. For example, diffusion tensor imaging (DTI) MRI
might be particularly suitable for tremor patients since Vim is a
functional rather than anatomical target, representing the entry zone
of the cerebello-dento-thalamic tract. We have successfully proved that
DTI MRI might be useful in targeting Vim with MRgFUS.37 DTI
MRI might be used to safely target smaller and riskier structures, such
as the subthalamus. In fact, although subthalamotomy is rarely perfor-
med because of the risk of hemiballism, we are aware of a few centers
trying to perform MRgFUS-subthalamotomies in PD patients.
MRgFUS is an incisionless procedure with no risk of infection,
cerebrospinal fluid leakage, and possibly bleeding. As for the last one,
the real risk is still unexplored, particularly in patients at risk such as in
the case of coagulopathy or anticoagulant use.
Finally, many patients are now requesting MRgFUS because they
like the non-invasive fashion of the procedure. Not surprisingly, studies
are now dealing with impressive placebo effects. For instance, a case
report of a PD patient has reported an impressive reduction of UPDRS
off medication but no changes in L-dopa equivalent daily dosage;40
more importantly, a still ongoing sham-controlled study has found a
non-significant effect of MRgFUS-thalamotomy at the 3-month visit
(primary endpoint) because of a 22% improvement in the sham group
(vs. 50% in the active treatment group).36
The (possible) future of MRgFUS in tremor conditions
Some of the possible future applications of MRgFUS listed in Table 3
are very close to an experimental application in humans. Among them,
‘‘enhanced sonication’’ might represent a future modality of perform-
ing lesions in tremor patients, particularly for patients with high skull
density and/or a too lateral target. The most promising application is
the possibility of neuromodulate brain circuits with high spatial resolu-
tion. In fact, MRgFUS can be used to change neuronal function with-
out causing lesion and ablation. The role of HIFU using temperatures
not able to induce permanent ablations is well known since it is used
for thalamic mapping during MRgFUS-thalamotomy. In some of
these cases, a sustained improvement of tremor even without ablating
the Vim has been reported.27 A similar approach has been successfully
used in the animal model of epilepsy.52
In addition to HIFU, another promising way to neuromodulate
brain targets is using LIFU, particularly with the so-called pulsed-
mode FUS.9,10
The neuromodulating property of FUS is probably related to
changes of voltage-gated ion channels and neuronal membrane
permeability resulting in modulation of action potentials.53,54
Animal experiments employed LIFU to stimulate the hippocampal,
motor cortex, and frontal eye field.53,55,56
In human volunteers stimulation of the primary sensory cortex
caused electroencephalography changes and tactile perception.57,58
Conclusion
Stereotactic brain lesioning has been used for decades and it is a
well-established effective treatment for medically refractory patients
with ET and certain patients with PD (asymmetric tremor-dominant
or dyskinetic patients).31 The scientific community shifted attention
from lesioning to DBS when the latter became the standard of
care. With the very recent FDA approval (July 2016) of MRgFUS-
thalamotomy for refractory unilateral ET, both preclinical and clinical
research on this technique are rapidly expanding for several indica-
tions. We are therefore witnessing a revival of ablative procedures.
In this article, we reviewed recent clinical trials and some of the
preclinical experimental works using MRgFUS for the treatment of
tremor.
MRgFUS seems to be an outstanding achievement in interventional
neurology and functional neurosurgery. This technology is the result of
developments in HIFU and modern MRI techniques. It is a non-
invasive and incisionless procedure able to ablate deep brain tissue, its
therapeutic effects are immediate, and patients can return quickly to
normal life. In contrast to RF ablative surgeries and DBS, MRgFUS
has no risk of infection and (possibly) bleeding and it does not use
ionizing irradiation. There are promising results of its effectiveness in
ET and other tremor syndromes. Other studies in other movement
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disorders and neurologic diseases are underway. There are also promising
results of MRgFUS in neuromodulation and focal disruption of the
BBB for therapeutic goals.
Our review has also emphasized the many problems and unknowns
related to this novel procedure. It is too early to draw definite con-
clusions on the value and unsolved issues of MRgFUS, but the good
news is that one more option is now available for tremor patients. We
believe that a deep understanding of the efficacy and safety of these
procedures is needed for the appropriate selection of the surgical
patients. Future studies comparing the different treatment modalities
are certainly needed.
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